US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

YARROW BIOSCIENCE, INC.

18.78

+0.04500.24%

Post-market: 19.240.4650+2.48%19:31 EDT

Volume:140.54K

Turnover:2.75M

Market Cap:158.44M

PE:-0.86

High:20.90

Open:18.67

Low:18.24

Close:18.73

52wk High:46.95

52wk Low:16.04

Shares:8.44M

Float Shares:8.37M

Volume Ratio:1.85

T/O Rate:1.68%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-21.8600

EPS(LYR):-66.8179

ROE:--

ROA:--

PB:-2.23

PE(LYR):-0.28

Loading ...

Overview Company News Filings

Bellevue Group Ag Reports 10.6% Passive Stake in Yarrow Bioscience as of Sept 10 - SEC Filing

THOMSON REUTERS

Yarrow Bioscience Closes $172.5 Million Public Offering

MT Newswires Live

U.S. Stocks on the MOVE-Novo Nordisk, Oracle, Adobe

Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering

Yarrow Bioscience Prices 5,769,231-Share Follow-on at USD 26, Raising USD 150 Million

Yarrow Bioscience, - Bioscience Prices Public Offering of 5,769,231 Shares at $26 Per Share

THOMSON REUTERS

Yarrow Bioscience Launches Underwritten Follow-on Stock Offering

Yarrow Bioscience Announces Proposed Underwritten Public Offering

THOMSON REUTERS

Yarrow Bioscience Files Amended 8-K Report on Merger Exchange Ratio Update

Yarrow Bioscience Q2 EPS $(2.14) Misses $(0.22) Estimate

Benzinga Earnings

Yarrow Bioscience Q2 FY26 Net Loss Narrows to $6.51 Million; R&D Expenses Rise to $4.94 Million

Yarrow Bioscience Inc: Net Loss Totaled $6.5 Million for the Second Quarter of 2026

THOMSON REUTERS

Press Release: Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update

BTIG Upgrades Yarrow Bioscience to Buy From Neutral, Price Target is $58

MT Newswires Live

Yarrow Bioscience Inc : Btig Initiates Coverage with Buy Rating; Target Price $58

THOMSON REUTERS

Vyne Therapeutics Issues Pre-funded Warrants for 133,290 Shares in Stock Exchange Deal

Yarrow Bioscience Finalizes Merger with VYNE, Starts Phase 2 Trial for Graves' Disease Drug YB-101

Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101

MT Newswires Live

Press Release: Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of Yb-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease

VYNE Therapeutics trading halted, news pending

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/YARW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"YARW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"YARW\",,,,,undefined,":{"symbol":"YARW","market":"US","secType":"STK","nameCN":"YARROW BIOSCIENCE, INC.","latestPrice":18.775,"timestamp":1791403200000,"preClose":18.73,"halted":0,"volume":140542,"hourTrading":{"tag":"盘后","latestPrice":19.24,"preClose":18.775,"latestTime":"19:31 EDT","volume":401,"amount":7576.635,"timestamp":1791415890399,"change":0.465,"changeRate":0.024767,"amplitude":0.024767},"delay":0,"changeRate":0.0024025627335823893,"floatShares":8374039,"shares":8439000,"eps":-21.86,"marketStatus":"Not Yet Opened","change":0.045,"latestTime":"10-07 16:00:00 EDT","open":18.67,"high":20.9,"low":18.24,"amount":2751139.16382,"amplitude":0.142018,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-21.86,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791446400000},"marketStatusCode":0,"adr":0,"listingDate":1516856400000,"exchange":"NASDAQ","adjPreClose":18.73,"preHourTrading":{"tag":"盘前","latestPrice":18.4901,"preClose":18.73,"latestTime":"09:08 EDT","volume":9,"amount":161.28009,"timestamp":1791378524701,"change":-0.2399,"changeRate":-0.012808,"amplitude":0.047517},"postHourTrading":{"tag":"盘后","latestPrice":19.24,"preClose":18.775,"latestTime":"19:31 EDT","volume":401,"amount":7576.635,"timestamp":1791415890399,"change":0.465,"changeRate":0.024767,"amplitude":0.024767},"volumeRatio":1.854777},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"YARW\",,,,,undefined,":{"symbol":"YARW","floatShares":8374039,"roa":"--","roe":"--","lyrEps":-66.817882,"volumeRatio":1.854777,"shares":8439000,"dividePrice":0,"high":20.9,"amplitude":0.142018,"preClose":18.73,"low":18.24,"week52Low":16.04,"pbRate":"-2.23","week52High":46.95,"institutionHeld":0,"latestPrice":18.775,"eps":-21.86,"divideRate":0,"volume":140542,"delay":0,"ttmEps":-21.86,"open":18.67,"prevYearClose":29.005,"prevWeekClose":22.27,"prevMonthClose":22.52,"prevQuarterClose":22.52,"fiveDayClose":22.52,"twentyDayClose":29.11,"sixtyDayClose":35.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/YARW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"YARW","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-2.14},{"market":"US","date":"2026-07-27","symbol":"YARW","defaultRemindTime":1785159000000,"type":"split","dateTimestamp":1785124800000,"forFactor":50,"toFactor":1,"ratio":50},{"date":"2026-07-24","symbol":"YARW","amount":0.40242,"announcedDate":"2026-07-10","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-22","defaultRemindTime":1784899800000,"name":"VYNE Therapeutics Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-23","payableDate":"2026-07-22","currency":"USD","dateTimestamp":1784865600000,"payDate":"2026-07-23"},{"market":"US","date":"2026-05-15","symbol":"YARW","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"post","actualEps":-0.08},{"date":"2026-02-27","symbol":"YARW","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1772182800000,"name":null,"time":"Pre-MKt","dateTimestamp":1772168400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"YARW\",market:\"US\",,,undefined,":[{"executeDate":"2026-07-24","recordDate":"2026-07-22","paymentDate":"2026-07-23","value":0.40242,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"YARW\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1786680000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/YARW\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"YARW","date":"2026-10-06","current":-0.858875,"percent":0.4,"low":-1.001942,"twenty":-0.836808,"median":-0.418951,"eighty":-0.35915,"high":-0.280418,"avg":-0.560953,"sd":0.243989,"marketCap":188878528},"quantilePoints":[{"date":"2026-08-14","current":-0.421219,"twenty":-0.422047,"median":-0.421219,"eighty":-0.412759,"marketCap":119616000},{"date":"2026-08-21","current":-0.376652,"twenty":-0.421318,"median":-0.411606,"eighty":-0.406626,"marketCap":106960000},{"date":"2026-08-28","current":-0.37468,"twenty":-0.419405,"median":-0.408204,"eighty":-0.384934,"marketCap":106400000},{"date":"2026-09-04","current":-0.284461,"twenty":-0.414849,"median":-0.390135,"eighty":-0.352317,"marketCap":80780000},{"date":"2026-09-11","current":-0.280418,"twenty":-0.411162,"median":-0.381829,"eighty":-0.296963,"marketCap":79632000},{"date":"2026-09-18","current":-1.001942,"twenty":-0.422382,"median":-0.390801,"eighty":-0.302425,"marketCap":284527359},{"date":"2026-09-25","current":-0.854173,"twenty":-0.851618,"median":-0.408351,"eighty":-0.317176,"marketCap":242564691},{"date":"2026-10-02","current":-0.773245,"twenty":-0.84205,"median":-0.413824,"eighty":-0.345484,"marketCap":219582919},{"date":"2026-10-06","current":-0.665121,"twenty":-0.836808,"median":-0.418951,"eighty":-0.35915,"marketCap":188878528}],"updateTime":1791437055805},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"YARW\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673001103","title":"Bellevue Group Ag Reports 10.6% Passive Stake in Yarrow Bioscience as of Sept 10 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2673001103","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673001103?lang=en_us&edition=fundamental","pubTime":"2026-10-08 00:44","pubTimestamp":1791391495,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nFWN45T233:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","YARW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667273695","title":"Yarrow Bioscience Closes $172.5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2667273695","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667273695?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:46","pubTimestamp":1789418772,"startTime":"0","endTime":"0","summary":"Yarrow Bioscience  said late Monday it has closed its public offering of about 6.6 million shares, including the full exercise of an over-allotment option, raising some $172.5 million.Net proceeds will be used for research and development and for general corporate purposes, the clinical-stage company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","YARW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666363521","title":"U.S. Stocks on the MOVE-Novo Nordisk, Oracle, Adobe","url":"https://stock-news.laohu8.com/highlight/detail?id=2666363521","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666363521?lang=en_us&edition=fundamental","pubTime":"2026-09-11 19:38","pubTimestamp":1789126681,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Novo Nordisk, Oracle, AdobeSeptember 11 (Reuters)-U.S. stock index futures bounced back as oil prices cooled on Friday and investors pinned their hopes on the consumer inf","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL6N4530P6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5TLWC47.USD","ORCX","SGXZ51526630.SGD","BK4559","LU0985489474.SGD","LU0208291251.USD","LU1169589451.USD","IE00BLSP4239.USD","IE00BMPRXR70.SGD","IE00B19Z3B42.SGD","LU0861579265.USD","SG9999015952.SGD","LU0320765059.SGD","LU0081259029.USD","TDIV","OZEM","SGXZ99366536.SGD","LU2275660780.HKD","LU0965508806.USD","LU0154236417.USD","BK4566","LU0157215616.USD","LU2362540622.SGD","IE0002270589.USD","LU0557290698.USD","THNR","LU1815333072.USD","LU1935042215.USD","BK4534","LU0302445910.USD","BK4023","SORCLmain","LU0068578508.USD","ADBU","LU0980610538.SGD","LU0234572021.USD","BK4122","LU0353189763.USD","LU2326559502.SGD","SG9999015945.SGD","KR","LU1037948897.HKD","SG9999015978.USD","LU0942090050.USD","SG9999015986.USD","BK4548","BK4543","LU1623119135.USD","SGXZ81514606.USD","BK4137","YARW","IE00BQXX3C00.GBP","LU0289960550.SGD","LU2357305700.SGD","LU2746668974.SGD","LU2362541513.USD","LU1989763690.USD","LU1366333091.USD","LU1989764664.SGD","LU1093756168.USD","BK4532","LU2054465674.USD","LU0957808578.USD","LU0889565833.HKD","IE00B3S45H60.SGD","LU0472753341.HKD","LU0868494708.USD","IE00B19Z9505.USD","LU0965509010.AUD","LU0476273544.USD","LU0057025933.USD","PAWZ","BK4516","LU0006306889.USD","BK4139","IE00B19Z3581.USD","IE00B5949003.HKD","IE00BZ1G4Q59.USD","LU0289739343.SGD","LU0070302665.USD","LU0708995401.HKD","LU2237957902.USD","NVOH","LU0661504455.SGD","BK4554","LU0082616367.USD","IE00BMPRXQ63.HKD","LU0314104364.USD","LU1235294995.USD","ACVA","LU1935042991.SGD","ORCU","IE00B7SZLL34.SGD","LU1429558221.USD","LU1941712264.USD","LU1989772840.SGD","NVO","IGV","LU0965509101.SGD","LU0130102774.USD","IE00BN8TJ469.HKD","LU2746668461.USD","LU0957791311.USD","LU1934455863.HKD","LU0061474960.USD","LU2023251221.USD","LU2125154935.USD","LU2250418816.HKD","LU1093756325.SGD","LU1169590202.USD","CHWY","SG9999000418.SGD","LU0345770993.USD","LU0553294199.USD","LU1674673428.USD","IE00BKVL7J92.USD","BK4528","LU0444973449.USD","IE00BFXG0V08.USD","LU1852331112.SGD","LU1935043536.SGD","LU1674673691.USD","LU1201861249.SGD","OGIG","LU1119994496.HKD","LU1989772923.USD","LU1489326972.SGD","LU0256863811.USD","LU2317271919.USD","LU0353189680.USD","BK4504","LU0672654240.SGD","LU0342679015.USD","LU0868494617.USD","LU1803068979.SGD","BK4200","LU2087625088.SGD","LU2458330243.SGD","BK4567","LU0210536198.USD","LU0198837287.USD","LU0417517546.SGD","BK4197","LU1935042488.USD","LU0069063385.USD","LU0109391861.USD","LU1633808545.USD","LU0056508442.USD","IE00BFMHRM44.USD","LU1823568750.SGD","LU0234570918.USD","LU1261432733.SGD","LU1989764748.USD","LU2237957811.SGD","LU2543165471.USD","LU0314106906.USD","LU1548497426.USD","LU0444971666.USD","IE00B775SV38.USD","LU1691799644.USD","BK4581","LU1935043023.USD","LU2860962120.EUR","LU1046421795.USD","IE00BBT3K403.USD","BK4113","LU1084165304.USD","LU1934455277.USD","ADBE","SG9999003800.SGD","ORAC","LU1941712348.USD","BK4159","BK4097","LU2108987350.USD","LU2458330169.SGD","LU0477156953.USD","LU2089283258.USD","BK4547","IE00BQXX3F31.USD","LU2237438978.USD","ADBG","LU0323591593.USD","BK4592","SG9999011175.SGD","LU1815336760.USD","BK4527","LU2089284900.SGD","LU0792757196.USD","LU0889566641.SGD","LU1069347547.HKD","LU0949170772.SGD","LU1934455194.USD","BK4588","LU0965509283.SGD","LU1267930730.SGD","LU2095319765.USD","LU1712237335.SGD","LU1778281490.HKD","LU1720051108.HKD","IE00BMPRXN33.USD","ORCZ","LU0175139822.USD","ATO","IE0009356076.USD","LU1506573853.SGD","LU0289961442.SGD","LU2360032135.SGD","LU1989763427.SGD","LU1037948541.HKD","LU0545039389.USD","LU2360106780.USD","SG9999001424.SGD","LU1720051017.SGD","LU0345770308.USD","LU0433182093.SGD","LU1003077747.HKD","LU1642822529.SGD","LU1435385759.SGD","LU2210150020.SGD","LU2236285917.USD","LU0348723411.USD","LU1267930813.SGD","LU0345774631.USD","IE00BYQQ9H92.USD","IE00BQXX3D17.EUR","BK4007","BK4533","LU0878866978.SGD","LU2896262040.SGD","BK4538","LU0130517989.USD","LU0170899867.USD","ORCS","LU2210149790.SGD","LU0345774391.USD","PMTS","LU0719512351.SGD","LU2125154778.USD","NVOX","LU0320765489.SGD","ORCL","LU0648001328.SGD","IE00BLSP4452.SGD","LU2362541273.HKD","PPH","IE0004445239.USD","LU0158827948.USD","LU1366192091.USD","BK4170","BK4585","BK4599","LU0312595415.SGD","LU0109392836.USD","AENT","LU0511384066.AUD","LU1035773651.USD","NVOC","LU0738911758.USD","LU0106261372.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666512989","title":"Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2666512989","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666512989?lang=en_us&edition=fundamental","pubTime":"2026-09-11 09:11","pubTimestamp":1789089113,"startTime":"0","endTime":"0","summary":"BRIEF-Yarrow Bioscience Announces Pricing Of $150 Million Underwritten Public OfferingSept 10 (Reuters)-Yarrow Bioscience, Inc.YARW.O:YARROW BIOSCIENCE ANNOUNCES PRICING OF $150 MILLION UNDERWRITTEN P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nTUA5VG6K6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","YARW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666512984","title":"Yarrow Bioscience Prices 5,769,231-Share Follow-on at USD 26, Raising USD 150 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666512984","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666512984?lang=en_us&edition=fundamental","pubTime":"2026-09-11 09:11","pubTimestamp":1789089076,"startTime":"0","endTime":"0","summary":"Yarrow Bioscience prices 5,769,231-share follow-on at USD 26, raising USD 150 millionYarrow Bioscience priced an underwritten public offering of 5,769,231 common shares at USD 26 per share.Gross proce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL7kScSG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YARW","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666512607","title":"Yarrow Bioscience, - Bioscience Prices Public Offering of 5,769,231 Shares at $26 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2666512607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666512607?lang=en_us&edition=fundamental","pubTime":"2026-09-11 09:11","pubTimestamp":1789089060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nTUA5VG6K6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","YARW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666851348","title":"Yarrow Bioscience Launches Underwritten Follow-on Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2666851348","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666851348?lang=en_us&edition=fundamental","pubTime":"2026-09-11 04:03","pubTimestamp":1789070600,"startTime":"0","endTime":"0","summary":"Yarrow Bioscience launches underwritten follow-on stock offeringYarrow Bioscience launched an underwritten public offering of common stock, with pre-funded warrants available in lieu of shares.Underwr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDLb07MXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YARW","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666951310","title":"Yarrow Bioscience Announces Proposed Underwritten Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2666951310","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666951310?lang=en_us&edition=fundamental","pubTime":"2026-09-11 04:03","pubTimestamp":1789070580,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA1VB0BB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["YARW","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659916788","title":"Yarrow Bioscience Files Amended 8-K Report on Merger Exchange Ratio Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659916788","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659916788?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:16","pubTimestamp":1786652189,"startTime":"0","endTime":"0","summary":"Yarrow Bioscience files amended 8-K report on merger exchange ratio updateYarrow Bioscience filed an amended Form 8-K to update its audited financial statements to reflect the effects of the merger ex","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL730Jq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","YARW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659315608","title":"Yarrow Bioscience Q2 EPS $(2.14) Misses $(0.22) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659315608","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659315608?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:17","pubTimestamp":1786619844,"startTime":"0","endTime":"0","summary":"Yarrow Bioscience (NASDAQ:YARW) reported quarterly losses of $(2.14) per share which missed the analyst consensus estimate of $(0.22) by 872.73 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61169365/yarrow-bioscience-q2-eps-2-14-misses-0-22-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QID","QQQE","IYW","NDX","TQQY","QQQY","PSQ","MNQmain","FTEC","NVIW.SI",".IXIC","TECS","ONEQ","NQmain","QQQ","QQQJ","GPIQ","QLD","JEPQ","QQQM","YARW","QYLG","SQQQ","BK4007","TQQQ","QDTE","QQQA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659155003","title":"Yarrow Bioscience Q2 FY26 Net Loss Narrows to $6.51 Million; R&D Expenses Rise to $4.94 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659155003","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659155003?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:00","pubTimestamp":1786618851,"startTime":"0","endTime":"0","summary":"Yarrow Bioscience Q2 FY26 net loss narrows to $6.51 million; R&D expenses rise to $4.94 millionYarrow posted a net loss of $6.5 million in Q2 2026, with R&D expense of $4.9 million and G&A expense of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDLbNhQ98:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","YARW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659569251","title":"Yarrow Bioscience Inc: Net Loss Totaled $6.5 Million for the Second Quarter of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2659569251","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659569251?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:00","pubTimestamp":1786618802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA12KT2J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["YARW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659733155","title":"Press Release: Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659733155","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659733155?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:00","pubTimestamp":1786618800,"startTime":"0","endTime":"0","summary":"--  The Company initiated the Phase 2a/2b trial of YB-101 in patients with. Graves' disease , with or without concurrent thyroid eye disease. --  The Phase 2a portion of the trial is a randomized,four cohorts designed to evaluate safety, pharmacokinetics ,pharmacodynamics , and efficacy over 24 weeks, including the. percentage of patients who are euthyroid and off anti-thyroid. drugs, as well as relevant measures of orbitopathy in patients. --  Topline results from the Phase 2a portion of the trial are. --  The Phase 2b portion of the trial is expected to commence in the. --  Licensing partner, Changchun GeneScience Pharmaceutical Co., Ltd.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4187","BK4585","FOWF","BK4173","BK4218","BK4588","PD","TSHR","SHLD","BK4181","KBWY","LU1169589451.USD","LU0170899867.USD","BK4516","BK4566","WDGF","GD","BK4550","YARW","PK","BK4007","IDEF","PPA","YB","BK4023","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656753413","title":"BTIG Upgrades Yarrow Bioscience to Buy From Neutral, Price Target is $58","url":"https://stock-news.laohu8.com/highlight/detail?id=2656753413","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656753413?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:20","pubTimestamp":1785756019,"startTime":"0","endTime":"0","summary":"BTIG Upgrades Yarrow Bioscience to Buy From Neutral, Price Target is $58","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","YARW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656237889","title":"Yarrow Bioscience Inc : Btig Initiates Coverage with Buy Rating; Target Price $58","url":"https://stock-news.laohu8.com/highlight/detail?id=2656237889","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656237889?lang=en_us&edition=fundamental","pubTime":"2026-08-03 18:27","pubTimestamp":1785752837,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nFWN4400UY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["YARW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655038533","title":"Vyne Therapeutics Issues Pre-funded Warrants for 133,290 Shares in Stock Exchange Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2655038533","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655038533?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:13","pubTimestamp":1785442414,"startTime":"0","endTime":"0","summary":"Vyne Therapeutics issues pre-funded warrants for 133,290 shares in stock exchange dealVyne Therapeutics entered an exchange agreement to issue pre-funded warrants for 133,290 common shares in exchange","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDLdzd4l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YARW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172460343","title":"Yarrow Bioscience Finalizes Merger with VYNE, Starts Phase 2 Trial for Graves' Disease Drug YB-101","url":"https://stock-news.laohu8.com/highlight/detail?id=1172460343","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172460343?lang=en_us&edition=fundamental","pubTime":"2026-07-27 22:01","pubTimestamp":1785160880,"startTime":"0","endTime":"0","summary":"Clinical-stage biotechnology company Yarrow Bioscience announced today that it has completed its merger with VYNE Therapeutics, simultaneously closing a roughly $200 million private placement...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VYNE","YARW","YB","BK4173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654043338","title":"Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2654043338","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654043338?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:17","pubTimestamp":1785158242,"startTime":"0","endTime":"0","summary":"Yarrow Bioscience  said Monday that it has completed its merger with VYNE Therapeutics and the previously announced private financings totaling approximately $200 million.The combined company will operate as Yarrow Bioscience and its shares are expected to begin trading on the Nasdaq Capital Market on Tuesday under the ticker symbol YARW.The combined company will be led by President and Chief Executive Officer Rebecca Frey, Chief Operating Officer Rachael Alford, and Chief Financial Officer Tyler Zeronda.Bill Lundberg, former chief executive of biotech firm Merus, will become chairman of the board of directors.Yarrow said its lead product candidate, YB-101, is a potential first-in-class anti-thyroid-stimulating hormone receptor monoclonal antibody designed to directly disrupt the central mechanism driving both Graves' disease and thyroid eye disease in a single targeted treatment.The company also said it has initiated dosing in a Phase 2a/2b trial of YB-101 in patients with Graves' dis","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VYNE","YARW","YB","BK4007","BK4173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654145380","title":"Press Release: Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of Yb-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2654145380","media":"Dow Jones","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654145380?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150000,"startTime":"0","endTime":"0","summary":"Yarrow is advancing YB-101--a potential first-in-class anti-TSHR antibody, designed to directly disrupt the central mechanism driving both Graves' disease (\"GD\") and thyroid eye disease (\"TED\")Dosing ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","YARW","YB","VYNE","BK4173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654586460","title":"VYNE Therapeutics trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2654586460","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654586460?lang=en_us&edition=fundamental","pubTime":"2026-07-25 07:50","pubTimestamp":1784937027,"startTime":"0","endTime":"0","summary":"19:50 EDT VYNE Therapeutics (VYNE) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaki...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vyne-therapeutics-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vyne-therapeutics-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["YARW","BK4007","VYNE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}]}}